Dataset Information

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

ABSTRACT: This phase I trial is studying the side effects and best dose of vorinostat in treating patients with metastatic or unresectable solid tumors or lymphoma and liver dysfunction. (closed for accrual as of 04/05/2010) Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Vorinostat may have different effects in patients who have changes in their liver function.

DISEASE(S): Extranodal Marginal Zone B-cell Lymphoma Of Mucosa-associated Lymphoid Tissue,Lymphoma, Large B-cell, Diffuse,Adult Grade Iii Lymphomatoid Granulomatosis,Stage Iv Adult T-cell Leukemia/lymphoma,Stage Iv Adult Diffuse Large Cell Lymphoma,Lymphoma, Large-cell, Immunoblastic,Small Intestine Lymphoma,Stage Iv Adult Diffuse Mixed Cell Lymphoma,Stage Iv Adult Immunoblastic Large Cell Lymphoma,Recurrent Grade 1 Follicular Lymphoma,Sezary Syndrome,Adult Nasal Type Extranodal Nk/t-cell Lymphoma,Splenic Marginal Zone Lymphoma,Mycosis Fungoides,Lymphoma, Mantle-cell,Stage Iv Adult Lymphoblastic Lymphoma,Stage Iii Adult Burkitt Lymphoma,Leukemia-lymphoma, Adult T-cell,Stage Iii Adult Diffuse Small Cleaved Cell Lymphoma,Recurrent Adult Immunoblastic Large Cell Lymphoma,Stage Iv Grade 1 Follicular Lymphoma,Recurrent Adult Burkitt Lymphoma,Stage Iv Mantle Cell Lymphoma,Lymphomatoid Granulomatosis,Primary Central Nervous System Non-hodgkin Lymphoma,Leukemia, T-cell,Lymphoma, T-cell, Peripheral,Lymphoma, Extranodal Nk-t-cell,Plasmablastic Lymphoma,Stage Iv Mycosis Fungoides/sezary Syndrome,Lymphoma, B-cell, Marginal Zone,Burkitt Lymphoma,Stage Iii Mycosis Fungoides/sezary Syndrome,Recurrent Adult Diffuse Small Cleaved Cell Lymphoma,Stage Iii Grade 1 Follicular Lymphoma,Stage Iii Adult Immunoblastic Large Cell Lymphoma,Nodal Marginal Zone B-cell Lymphoma,Stage Iii Marginal Zone Lymphoma,Stage Iii Adult Diffuse Mixed Cell Lymphoma,Recurrent Small Lymphocytic Lymphoma,Lymphoma, T-cell, Cutaneous,Stage Iv Adult Burkitt Lymphoma,Recurrent Marginal Zone Lymphoma,Stage Iii Adult T-cell Leukemia/lymphoma,Recurrent Adult Grade Iii Lymphomatoid Granulomatosis,Lymphoma, Follicular,Waldenstrom Macroglobulinemia,Stage Iii Adult Diffuse Large Cell Lymphoma,Leukemia, Lymphocytic, Chronic, B-cell,Intraocular Lymphoma,Stage Iii Cutaneous T-cell Non-hodgkin Lymphoma,Recurrent Mantle Cell Lymphoma,Recurrent Grade 3 Follicular Lymphoma,Stage Iii Adult Hodgkin Lymphoma,Leukemia,Hodgkin Disease,Recurrent Adult Hodgkin Lymphoma,Primary Central Nervous System Hodgkin Lymphoma,Mycoses,Stage Iii Grade 2 Follicular Lymphoma,Waldenström Macroglobulinemia,Recurrent Adult Lymphoblastic Lymphoma,Angioimmunoblastic T-cell Lymphoma,Stage Iv Marginal Zone Lymphoma,Unspecified Adult Solid Tumor, Protocol Specific,Lymphoma, Large-cell, Anaplastic,Stage Iv Adult Hodgkin Lymphoma,Stage Iii Mantle Cell Lymphoma,Lymphoma, T-cell,Stage Iii Grade 3 Follicular Lymphoma,Stage Iv Grade 3 Follicular Lymphoma,Stage Iv Adult Diffuse Small Cleaved Cell Lymphoma,Immunoblastic Lymphadenopathy,Precursor Cell Lymphoblastic Leukemia-lymphoma,Recurrent Cutaneous T-cell Non-hodgkin Lymphoma,Stage Iv Small Lymphocytic Lymphoma,Lymphoma,Recurrent Mycosis Fungoides/sezary Syndrome,Anaplastic Large Cell Lymphoma,Recurrent Adult Diffuse Mixed Cell Lymphoma,Stage Iii Small Lymphocytic Lymphoma,Recurrent Grade 2 Follicular Lymphoma,Stage Iv Cutaneous T-cell Non-hodgkin Lymphoma,Stage Iv Grade 2 Follicular Lymphoma,Recurrent Adult T-cell Leukemia/lymphoma,Lymphoma, Non-hodgkin,Stage Iii Adult Lymphoblastic Lymphoma,Recurrent Adult Diffuse Large Cell Lymphoma,Lymphoma, B-cell,Cutaneous B-cell Non-hodgkin Lymphoma

PROVIDER: 2041970 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer [NPC], and squamous cell carcinoma of the head and neck [SCCHN]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis (closed to accrual) 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07/27/2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) 24. Pheochromocytoma, malignant (closed to accrual) 25. Paraganglioma (closed to accrual 11/29/2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex (closed to accrual) 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09/19/2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11/29/2018) 31. Adrenal cortical tumors (closed to accrual 06/27/2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12/22/2017) 33. Not Otherwise Categorized (NOC) Rare Tumors [To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org] (closed to accrual 03/15/2019) 34. Adenoid cystic carcinoma (closed to accrual 02/06/2018) 35. Vulvar cancer (closed to accrual) 36. MetaPLASTIC carcinoma (of the breast) (closed to accrual) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09/26/2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors/extramammary Paget’s disease (closed to accrual) 40. Peritoneal mesothelioma 41. Basal cell carcinoma (temporarily closed to accrual 04/29/2020) 42. Clear cell cervical cancer 43. Esthenioneuroblastoma (closed to accrual) 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell endometrial cancer 46. Clear cell ovarian cancer (closed to accrual) 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 53). Small cell lung cancer is not eligible (closed to accrual) 53. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)

Dataset Information

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure